High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 75-81

  Liga, Maria ^a   Triantafyllou, Evangelia ^a   Tiniakou, Maria ^a   Lambropoulou, Polyxeni ^a   Karakantza, Marina ^a   Zoumbos, Nicholas C ^a   Spyridonidis, Alexandros ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Leukemia; Prophylactic DLI; Relapse

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CD3+ T LYMPHOCYTE; CHIMERA; CONDITIONING; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RELAPSE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84871928351     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.07.021     Document Type: Article

References (38)

1. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
2. Spyridonidis A., Labopin M., Schmid C., et al. Immunotherapy Subcommittee of the Acute Leukemia Working Party. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation: an analysis on behalf of the Acute Leukemia Working Party of the EBMT. Leukemia 2012, 26:1211-1217.
3. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions. The long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.
4. Liesveld J.L., Rothberg P.G. Mixed chimerism in SCT: conflict or peaceful coexistence?. Bone Marrow Transplant 2008, 42:297-310.
5. Michaelis L., Lin S., Joseph L., et al. Chimerism does not predict for outcome after alemtuzumab-based conditioning (letter). Bone Marrow Transplant 2007, 40:181.
6. Lim Z.Y., Pearce L., Ingram W., et al. Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transplant 2008, 41:587-588.
7. van Besien K., Dew A., Lin S., et al. Patterns and kinetics of T-cell chimerism after allotransplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009, 50:1809-1817.
8. Barrios M., Jimenez-Velasco A., Roman-Gomez J., et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003, 88:801-810.
9. Zeiser R., Spyridonidis A., Wasch R., et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005, 19:814-821.
10. Spyridonidis A., Zeiser R., Wasch R., et al. Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantation. Clin Transplant 2005, 19:350-356.
11. Horky O., Mayer J., Kablaskova L., et al. Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse. Int J Lab Hematol 2011, 33:57-66.
12. Rettinger E., Willasch A.M., Kreyenberg H., et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011, 118:5681-5688.
13. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.
14. Marks D.I., Lush R., Cavenagh J., et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002, 100:3108-3114.
15. Peggs K.S., Kayani I., Edwards N., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011, 29:971-978.
16. Spyridonidis A., Liga M., Triantafyllou E., et al. Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. Bone Marrow Transplant 2011, 46:1363-1368.
17. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
19. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-956.
20. Naparstek E., Or R., Nagler A., et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995, 89:506-515.
21. Barrett A.J., Mavroudis D., Tisdale J., et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998, 21:543-551.
22. de Lima M., Bonamino M., Vasconcelos Z., et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001, 27:73-78.
23. Schaap N., Schattenberg A., Bar B., et al. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukemia 2001, 15:1339-1346.
24. + T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002, 8:625-632.
25. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
26. Montero A., Savani B.N., Shenoy A., et al. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biol Blood Marrow Transplant 2006, 12:1318-1325.
27. Lutz C., Massenkeil G., Nagy M., et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:805-812.
28. Raiola A.M., van Lint M.T., Valbonesi M., et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003, 31:687-693.
29. Huang X., Guo N., Ren H., et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J 2003, 116:736-741.
30. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002, 20:405-412.
31. Kim J.G., Sohn S.K., Kim D.H., et al. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant 2004, 33:231-236.
32. Hasskarl J., Zerweck A., Wasch R., et al. Induction of graft-versus-malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant 2012, 47:277-282.
33. Metaxas Y., Bertz H., Spyridonidis A., et al. CT60 single-nucleotide polymorphism as a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia. Bone Marrow Transplant 2012, 47:411-415.
34. Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004, 103:790-795.
35. von dem Borne P.A., Beaumont F., Starrenburg C.W., et al. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006, 91:1559-1562.
36. Bacher U., Haferlach T., Fehse B., et al. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia. ScientificWorldJournal 2011, 11:310-319.
37. Ciceri F., Bonini C., Marktel S., et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007, 109:4698-4707.
38. di Stasi A., Tey S.K., Dotti G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.